{"id":46743,"date":"2022-07-29T17:01:41","date_gmt":"2022-07-29T15:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/"},"modified":"2022-07-29T17:01:41","modified_gmt":"2022-07-29T15:01:41","slug":"progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382725\/progesterone-receptor-pr-antagonist-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rlfvx8&amp;utm_campaign=1732671+-+Progesterone+Receptor+(PR)+Antagonist+Pipeline+Research+Report+2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg\"><\/a><\/p>\n<p>\n&#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development.\n<\/p>\n<p>\nThe report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.\n<\/p>\n<p>\n<strong>Descriptive coverage of pipeline development activities for Progesterone Receptor (PR) Antagonist<\/strong>\n<\/p>\n<p>\nPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.\n<\/p>\n<p>\n<strong>Pipeline Therapeutics assessment of products for Progesterone Receptor (PR) Antagonist<\/strong>\n<\/p>\n<p>\nThe report assesses the active Progesterone Receptor (PR) Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.\n<\/p>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nProvides a snapshot of the therapeutics pipeline activity for Progesterone Receptor (PR) Antagonist\n<\/li>\n<li>\nFeatures the Progesterone Receptor (PR) Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages\n<\/li>\n<li>\nOffers detailed therapeutic product profiles of Progesterone Receptor (PR) Antagonist with key coverage of developmental activities including licensing &amp; collaboration deals, patent details, designations, technologies, indications and chemical information\n<\/li>\n<li>\nTherapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration\n<\/li>\n<li>\nCoverage of dormant and discontinued pipeline projects across Progesterone Receptor (PR) Antagonist\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Progesterone Receptor (PR) Antagonist &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>3. Pipeline Therapeutics<\/strong>\n<\/p>\n<ul>\n<li>\nAn Overview of Pipeline Products for Progesterone Receptor (PR) Antagonist\n<\/li>\n<\/ul>\n<p>\n<strong>4. Comparative Analysis<\/strong>\n<\/p>\n<p>\n<strong>5. Progesterone Receptor (PR) Antagonist Pipeline Products in Clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>6. Progesterone Receptor (PR) Antagonist Pipeline Products in Non-clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>7. Therapeutic Assessment: Active Products<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Assessment by Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Stage and Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Molecule Type\n<\/li>\n<li>\nPipeline Assessment by Stage and Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>8. Inactive Pipeline Products<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<li>\nReason for dormancy\/discontinuation\n<\/li>\n<\/ul>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nArno Therapeutics\n<\/li>\n<li>\nBayer HealthCare Pharmaceuticals\n<\/li>\n<li>\nMinerva Neurosciences\n<\/li>\n<li>\nRepros Therapeutics\n<\/li>\n<li>\nBayer Schering Pharma\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382725\/progesterone-receptor-pr-antagonist-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rlfvx8&amp;utm_campaign=1732671+-+Progesterone+Receptor+(PR)+Antagonist+Pipeline+Research+Report+2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/2n0v6e<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;p&#114;&#x65;&#115;&#x73;&#64;&#114;&#x65;s&#x65;a&#114;&#x63;h&#x61;&#x6e;&#100;&#x6d;a&#114;&#x6b;&#101;&#x74;s&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#x65;s&#115;&#x40;r&#101;&#x73;&#x65;&#97;&#x72;&#x63;h&#97;&#x6e;d&#109;&#x61;&#x72;&#107;&#x65;&#x74;s&#46;&#x63;o&#109;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development. The report provides detailed coverage of the pipeline landscape for &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46743","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development. The report provides detailed coverage of the pipeline landscape for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-29T15:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-29T15:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/\"},\"wordCount\":438,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005369\\\/en\\\/1529415\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/\",\"name\":\"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005369\\\/en\\\/1529415\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-29T15:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005369\\\/en\\\/1529415\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005369\\\/en\\\/1529415\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Progesterone Receptor (PR) Antagonist &#8211; Pipeline Insight, 2022&#8221; offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development. The report provides detailed coverage of the pipeline landscape for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-29T15:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-07-29T15:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/"},"wordCount":438,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/","name":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg","datePublished":"2022-07-29T15:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220729005369\/en\/1529415\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/progesterone-receptor-pr-antagonist-pipeline-research-report-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Progesterone Receptor (PR) Antagonist Pipeline Research Report 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46743"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46743\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}